Bo Kara heads up the Process Development team for Advanced Therapy Delivery at GSK. He has over 25 years’ experience in designing research and development programmes to develop scaleable and validatable manufacturing processes for recombinant protein products. He has published widely and is primary inventor on a range of process/expression patents. He has developed a keen understanding of the technical, regulatory and commercial issues faced at each stage of the development of manufacturing processes for biopharmaceuticals.
Bo Kara will be discussing manufacturing ex-vivo cell & gene therapy for rare disease and oncology applications, expression and manufacturing platforms for lentivirus production and CAR-T, upscaling to improve patient access and attepting to answer the question what does the future hold for this area of manufacturing?